Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial
- 30 September 2008
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 156 (3) , 528-536.e5
- https://doi.org/10.1016/j.ahj.2008.05.015
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (U01 HL061744, U01 HL061746, U01 HL061748, U01 HL063804)
- National Heart, Lung, and Blood Institute
This publication has 21 references indexed in Scilit:
- Optimal Medical Therapy with or without PCI for Stable Coronary DiseaseNew England Journal of Medicine, 2007
- Rationale for the Revascularization Arm of the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) TrialThe American Journal of Cardiology, 2006
- Rationale, Design, and Methods for Glycemic Control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) TrialThe American Journal of Cardiology, 2006
- Modifications of Coronary Risk FactorsPublished by Elsevier ,2006
- Hypotheses, Design, and Methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) TrialThe American Journal of Cardiology, 2006
- ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention—Summary ArticleCirculation, 2006
- ADVANCE—Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baselineDiabetic Medicine, 2005
- The Coronary ArteryRevascularisation in Diabetes (CARDia) trial: Background, aims, and designAmerican Heart Journal, 2005
- Thirty-year Trends in Cardiovascular Risk Factor Levels among US Adults with Diabetes: National Health and Nutrition Examination Surveys, 1971-2000American Journal of Epidemiology, 2004
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998